[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334765-105":59,"doc-detail-334765-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unraveling-the-global-proteome-and-phosphoproteome-of-prostate-cancer-patient-derived-xenografts","Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts","","Resistance to androgen-deprivation therapy drives metastatic castration-resistant prostate cancer (mCRPC) that can evolve into aggressive variant prostate cancer (AVPC) with neuroendocrine-like features. Proteome and phosphoproteome profiling was performed on 48 LuCaP patient-derived xenograft (PDX) tumors, identifying over 94,000 peptides and 9,700 phosphopeptides mapped to thousands of proteins. Comparisons across neuroendocrine-like versus adenocarcinoma samples revealed hundreds of significantly altered proteins and phosphopeptides, with discordance patterns reflecting transcriptional regulation and metabolic enzyme differences. Results highlight protein-based identification and provide targets for clinical assay development and mechanistic tumor biology studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unraveling-the-global-proteome-and-phosphoproteome-of-prostate-cancer-patient-derived-xenografts/334765/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unraveling-the-global-proteome-and-phosphoproteome-of-prostate-cancer-patient-derived-xenografts/334765.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the study address in prostate cancer?","Question",{"text":112,"@type":113},"The study addresses resistance to androgen-deprivation therapy, which can lead to metastatic castration-resistant prostate cancer and emergence of more aggressive variant phenotypes with neuroendocrine-like features.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What experimental models and omics data were used?",{"text":117,"@type":113},"LuCaP patient-derived xenograft tumors were profiled using proteome and phosphoproteome characterization, analyzing 48 PDX tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How were neuroendocrine-like and adenocarcinoma samples compared?",{"text":121,"@type":113},"The study compared neuroendocrine-like versus adenocarcinoma samples using biological replicates and multiple PDX tumor groupings, identifying significantly altered proteins and phosphopeptides associated with the two phenotypes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334765,1790555160,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts  \nZoi E. Sychev1, Abderrahman Day2,3, Hannah E. Bergom2, Gabrianne Larson1, Atef Ali2, Megan Ludwig1, Ella Boytim2, Ilsa Coleman4, Eva Corey5, Stephen R. Plymate5,6,7, Peter S. Nelson4, Justin H. Hwang2,8,9, and Justin M. Drake1,9,10  \nABSTRACT  \n◥  \nResistance to androgen-deprivation therapies leads to metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma (AdCa) origin that can transform into emergent aggressive variant prostate cancer (AVPC), which has neuroendocrine (NE)-like features. In this work, we used LuCaP patient-derived xenograft (PDX) tumors, clinically relevant models that reﬂect and retain key features of the tumor from advanced prostate cancer patients. Here we performed proteome and phosphoproteome characterization of 48 LuCaP PDX tumors and identiﬁed over 94,000 peptides and 9,700 phosphopeptides corresponding to 7,738 proteins. We compared 15 NE versus 33 AdCa samples, which included six different PDX tumors for each group in biological replicates, and identiﬁed  \n309 unique proteins and 476 unique phosphopeptides that were signiﬁcantly altered and corresponded to proteins that are known to distinguish these two phenotypes. Assessment of concordance from PDX tumor-matched protein and mRNA revealed increased dissonance in transcriptionally regulated proteins in NE and metabolite interconversion enzymes in AdCa.  \nImplications: Overall, our study highlights the importance of protein-based identiﬁcation when compared with RNA and provides a rich resource of new and feasible targets for clinical assay development and in understanding the underlying biology of these tumors.  \nIntroduction  \nProstate cancer is the most diagnosed cancer in men in the United States. Early detection via regular screening of serum prostate-speciﬁc antigen (PSA) levels has facilitated prostate cancer diagnosis in organconﬁned tumors before cancer spreads (1) . If a patient presents with aggressive prostate cancer, a classic upfront therapy involves radiation or surgery with androgen-deprivation therapy (ADT; refs. 2, 3) . Although ADT response is effective initially, tumors progress to amore aggressive disease known as metastatic castration-resistance prostate cancer (mCRPC; refs. 3, 4) . Treatment of mCRPC with adenocarcinoma (AdCa) features consists of hormonal therapies such as enzalutamide, abiraterone acetate, darolutamide, and apalutamide; however, these therapies can often induce novel phenotypes such as aggressive variant prostate cancer (AVPC) . AVPC has genetic aberrations, including PTENand RB1 loss, TP53 mutations, and diminished  \n1Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota. 2Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. 3Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota. 4Fred Hutchinson Cancer Center, Seattle, Washington. 5Department of Urology, University of Washington, Seattle, Washington. 6Division of Gerontology and Geriatrics Medicine, University of Washington, Seattle, Washington. 7Geriatric Research Education and Clinical Center, Seattle Veterans Affairs Medical Center, Seattle Washington. 8Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota. 9Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 10Department of Urology, University of Minnesota, Minneapolis, Minnesota.  \nCorresponding Author: Justin M. Drake, Department of Pharmacology, University of Minnesota Medical School, 6-120 Jackson Hall, Minneapolis, MN 55455 . E-mail: [jdrake@umn.edu](jdrake@umn.edu)  \nMol Cancer Res 2024;22:452–64  \ndoi: 10.1158/1541-7786 . MCR-23-0976  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4 . 0 International (CC BY-NC-ND 4 . 0) license.  \n􀀁2024The Authors;Published by the Am","cbCaijL2hMsJSQcd","https://ap.wps.com/l/cbCaijL2hMsJSQcd","pdf",14516729,13,"English","# Abstract\n# Introduction\n## Androgen-deprivation therapy and progression to mCRPC\n## AVPC phenotypes and unmet clinical need\n## Genomic aberrations shaping mCRPC subtypes","[{\"question\":\"What clinical problem does the study address in prostate cancer?\",\"answer\":\"The study addresses resistance to androgen-deprivation therapy, which can lead to metastatic castration-resistant prostate cancer and emergence of more aggressive variant phenotypes with neuroendocrine-like features.\"},{\"question\":\"What experimental models and omics data were used?\",\"answer\":\"LuCaP patient-derived xenograft tumors were profiled using proteome and phosphoproteome characterization, analyzing 48 PDX tumors.\"},{\"question\":\"How were neuroendocrine-like and adenocarcinoma samples compared?\",\"answer\":\"The study compared neuroendocrine-like versus adenocarcinoma samples using biological replicates and multiple PDX tumor groupings, identifying significantly altered proteins and phosphopeptides associated with the two phenotypes.\"}]","Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts | PDF",1790008279,33]